(Q44632323)

4 December 2017

Determinants for sustained HBeAg response to lamivudine therapy (English)

1 reference

4 December 2017

1 reference

5

0 references

author name string

Rong-Nan Chien

1

1 reference

4 December 2017

Chau-Ting Yeh

2

1 reference

4 December 2017

Sun-Lung Tsai

3

1 reference

4 December 2017

Chia-Ming Chu

4

1 reference

4 December 2017

language of work or name

English

0 references

publication date

1 November 2003

1 reference

full work available at URL

4 December 2017

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1053/jhep.2003.50458

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14578866

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1053%2Fjhep.2003.50458

25 March 2024

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50458

https://onlinelibrary.wiley.com/doi/full/10.1053/jhep.2003.50458

25 March 2024

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50458

25 March 2024

1 reference

4 December 2017

38

1 reference

4 December 2017

5

1 reference

4 December 2017

1267-1273

1 reference

Review: Present and future directions in the treatment of chronic hepatitis B infection

4 December 2017

1

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50458

Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group

25 March 2024

2

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50458

Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.

25 March 2024

3

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50458

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

25 March 2024

4

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50458

Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy.

25 March 2024

5

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50458

Durability of serologic response after lamivudine treatment of chronic hepatitis B.

25 March 2024

6

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50458

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

25 March 2024

7

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50458

Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion

25 March 2024

8

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50458

Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation

25 March 2024

9

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50458

Cytotoxic T cells and viral hepatitis

25 March 2024

11

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50458

Comparison of the amino acid sequences of nine different serotypes of hepatitis B surface antigen and genomic classification of the corresponding hepatitis B virus strains

25 March 2024

12

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50458

Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus--large-scale analysis using a new genotyping method

25 March 2024

13

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50458

Hepatitis B viral genotypes: clinical relevance and molecular characteristics.

25 March 2024

14

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50458

Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B

25 March 2024

15

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50458

Hepatitis B genotypes and the response to interferon therapy

25 March 2024

16

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50458

Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B

25 March 2024

18

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50458

Clinical relevance of hepatitis B viral mutations

25 March 2024

19

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50458

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

25 March 2024

20

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50458

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

25 March 2024

21

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50458

Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region. Core Working Party for Asia-Pacific Consensus on Hepatitis B and C

25 March 2024

22

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50458

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

25 March 2024

24

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50458

Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy

25 March 2024

25

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50458

Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease

25 March 2024

27

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50458

Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers

25 March 2024

28

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50458

Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C.

25 March 2024

29

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50458

Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase

25 March 2024

31

1 reference

https://api.crossref.org/works/10.1053/JHEP.2003.50458

25 March 2024

Identifiers

1 reference

4 December 2017

1 reference